Desmoteplase in Subjects With Acute Ischemic Stroke (DIAS-4)
Ischemic strokes account for about 85 percent of all acute strokes. The only currently approved thrombolytic intervention for acute ischemic stroke is alteplase (recombinant tissue plasminogen activator rtPA). Its use is limited by the need to be administered within three hours after symptom onset. The thrombolytic agent desmoteplase or rDSPAalpha-1 is an alternative fibrin-specific plasminogen activator that presents several benefits: It is non-neurotoxic, it is highly specific, it has a prolonged half-life and it carries a lower risk of bleeding. This, in combination with evidence derived from previous clinical studies, indicates potential for better clinical efficacy in a time window extending up to nine hours following symptom onset.
DIAS-4 is a multinational, randomized, double-blind, parallel-group, placebo-controlled, phase III study designed to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke three to nine hours after symptom onset.
In order to participate you must meet the following criteria:
- Are an adult between 18 and 85 years of age.
- Are clinically diagnosed with acute ischemic stroke.
- Can receive treatment within three to nine hours after the onset of stroke symptoms.
You will be excluded from the study if any of the following criteria apply to you:
- Have a pre-stroke mRS>1 indicating previous disability.
- Have been previously exposed to desmoteplase.
- Have imaging evidence of ICH or SAH (regardless of age of bleeding), AV malformation, cerebral aneurysm or cerebral neoplasm.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message